文献速递银屑病与炎症性皮肤病

KLRB1与IL12RB1可预测IL-17阻断治疗银屑病患者的复发时间

KLRB1 and IL12RB1 are pretherapeutic predictors of time to relapse in patients with psoriasis treated with IL-17 blockade.
PubMed 文献 · J Am Acad Dermatol · 2025-11-28

该研究对23例接受依奇珠单抗(IL-17阻断剂)治疗的银屑病患者进行纵向皮肤转录组分析,覆盖基线、第8周PASI75及复发阶段。结论:基线KLRB1和IL12RB1升高者停药后复发风险更高。

要点

  • 基线KLRB1和IL12RB1高表达与依奇珠单抗停药后高复发风险相关。
  • 复发伴随CD4+记忆T细胞、树突状细胞和肥大细胞再激活。

核心结论

  • 基线KLRB1和IL12RB1水平升高的银屑病患者,停用依奇珠单抗后复发风险更高。

研究设计与样本

  • 纵向收集23例银屑病患者基线、第8周PASI75及复发阶段的皮肤转录组。
  • 采用迭代随机森林回归模型和SHAP值确定复发关键预测基因。

主要发现

  • 机器学习模型鉴定KLRB1和IL12RB1为关键预测基因,并经基线皮肤活检免疫荧光验证。
  • CD4+记忆T细胞、树突状细胞和肥大细胞再激活与复发相关,KLRB1和IL12RB1与这些免疫浸润细胞的活化状态正相关。

临床怎么用

  • 基线检测KLRB1和IL12RB1可能有助于识别停用IL-17阻断剂后高复发风险患者,辅助治疗决策。

局限性

  • 患者来自单中心,且均接受依奇珠单抗治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Relapse of psoriasis after the cessation of treatment remains an unresolved clinical challenge. OBJECTIVE: To identify predictors of risk of relapse in patients with psoriasis treated by interleukin (IL) 17 blockade (ixekizumab) and to investigate longitudinal dynamics driving relapse. METHODS: Longitudinal skin transcriptomes were collected from 23 patients across baseline, psoriasis area and severity index 75 at week 8, and relapse phases. An iterative random forest regression model and SHapley Additive exPlanation values were used to determine key predictive genes of relapse. Profiling of immune-infiltrating cells and time-series-based clustering were performed to identify longitudinal transcriptomic signatures. RESULTS: KLRB1 and IL12RB1 were identified as key predictive genes by a machine learning model and validated by immunofluorescence on baseline skin biopsies. Multivariable Cox regression built by KLRB1 and IL12RB1 stratified patients with high risk of relapse (log-rank test P = .0013). Reactivation of CD4+ memory T cells, dendritic cells, and mast cells was associated with relapse; KLRB1 and IL12RB1 were positively correlated with the activated state of these immune-infiltrating cells. LIMITATIONS: Patients were recruited from a single center, and all were treated with ixekizumab. CONCLUSION: Patients with psoriasis who exhibit elevated levels of KLRB1 and IL12RB1 at baseline have a higher risk of relapse after ixekizumab withdrawal.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wang H, Zhang L, Xu X, et al. KLRB1 and IL12RB1 are pretherapeutic predictors of time to relapse in patients with psoriasis treated with IL-17 blockade. J Am Acad Dermatol. 2025. PMID: 41319713. doi:10.1016/j.jaad.2025.11.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。